Blog
RSS FeedPosted by Michael Wonder on 10 Oct 2020
In landmark international program, HTA agencies around the world access ICER's customisable COVID-19 cost-effectiveness model
9 October 2020 - Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform ...
Posted by Michael Wonder on 29 Sep 2020
ICER to assess treatment for Alzheimer’s disease
29 September 2020 - Report will be subject of CTAF meeting in May 2021; open Input now being accepted until ...
Posted by Michael Wonder on 28 Sep 2020
ICER publishes white paper on cornerstones for fair patient access to prescription drugs, launches annual assessment of US payer policies
28 September 2020 - Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper ...
Posted by Michael Wonder on 23 Sep 2020
ICER issues final report and policy recommendations on treatments for cystic fibrosis
23 September 2020 - Independent appraisal committee unanimously concludes that Trikafta delivers substantial benefits for patients, family members, and society. ...
Posted by Michael Wonder on 22 Sep 2020
ICER posts draft scoping document on therapies for multiple myeloma
22 September 2020 - Document open to public comment until 13 October 2020. ...
Posted by Michael Wonder on 11 Sep 2020
ICER publishes evidence report on targeted immune modulator therapies for ulcerative colitis
11 September 2020 - All assessed therapies provide significant health benefits, but even after rebates, all are priced at levels ...
Posted by Michael Wonder on 31 Aug 2020
ICER posts draft scoping document on lupus nephritis
31 August 2020 - Document open to public comment until 21 September 2020. ...
Posted by Michael Wonder on 15 Aug 2020
Many psoriasis patients are paying higher prices than ever at the pharmacy counter
13 August 2020 - Over the past decade, wholesale prices for self-administered psoriasis medicines rose substantially, underscoring the ongoing financial ...
Posted by Michael Wonder on 10 Aug 2020
Coming of age: emerging health preference research based on established scientific standards
10 August 2020 - Value in Health themed section enhances the scientific respectability and relevance of health preference research. ...
Posted by Michael Wonder on 10 Aug 2020
ICER to assess treatments for lupus nephritis
10 August 2020 - Report will be subject of New England CEPAC meeting in March 2021; Open Input now being accepted ...
Posted by Michael Wonder on 22 Jul 2020
COVID-19 and ISPOR conferences
22 July 2020 - ISPOR redesigns remaining conferences for 2020. ...
Posted by Michael Wonder on 21 Jul 2020
ICER publishes evidence report on obeticholic acid for the treatment of non-alcoholic steatohepatitis
21 July 2020 - Given the FDA’s recent decision to not grant accelerated approval for the treatment, ICER has canceled its ...
Posted by Michael Wonder on 20 Jul 2020
ICER posts draft scoping document for the assessment of anaemia in chronic kidney disease treatments
20 July 2020 - Document open to public comment until 7 August 2020 ...
Posted by Michael Wonder on 08 Jul 2020
ICER reschedules cystic fibrosis public meeting for 27 August 2020
8 July 2020 - Registration is now open. ...
Posted by Michael Wonder on 06 Jul 2020
ICER posts draft scoping document on high cholesterol
6 July 2020 - Document open to public comment until 24 July 2020. ...